Daily non-political popular news in brief.

Application of Genomatix in silico methods reveals novel cancer associated genes

Genomatix Software GmbH, an in silico systems biology company with headquarter in Munich, Germany, released today that researcher in Dublin, Ireland, and Boston, Mass., USA, identified novel cancer associated genes, based on strategies and products developed and promoted by Genomatix. Experimental verification by siRNA knock-down and RT-PCR confirmed the in silico results.

Read more »

Keywords: application, genomatix, silico, methods, reveals, novel, cancer, associated, genes, method, reveal, gene

« Previous | Next »

Similar news on "Application of Genomatix in silico methods reveals novel cancer associated genes":

1. Cold Spring Harbor scientists devise novel, low-cost method of sifting genome's high-value regions
   11-06-2007 · EurekAlert!
   Scientists at Cold Spring Harbor Laboratory have developed a new means of extracting and interpreting data from the human genome that is more powerful and more economical than methods currently employed. The new technology, called selective resequencing, promises to be a boon to many kinds of research, including efforts to comb vast stretches of the genome for mutant genes implicated in major diseases such as cancer and schizophrenia.
   Similar news · Read more »
   
2. Advance in understanding of blood pressure gene could lead to new treatments
   02-04-2007 · EurekAlert!
   Research by scientists at UCL (University College London) has clearly demonstrated for the first time the structure and function of a gene crucial to the regulation of blood pressure. The discovery could be important in the search for new treatments for illnesses such as heart disease, the UK's biggest killer. In a paper published online today in Nature Medicine, the team, led by Professor Patrick Vallance and Dr James Leiper, UCL Department of Medicine, reveal the role of the human gene dimethylarginine dimethylaminohydrolase (DDAH), showing that loss of DDAH activity disrupts nitric oxide (NO) production. NO is critical in the regulation of blood pressure, nervous system functions and the immune system. The role of DDAH is to break down modified amino acids (Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA)) that are produced by the body and have been shown to inhibit NO synthase. These molecules accumulate in various disease states including diabetes, renal failure and pulmonary and systemic hypertension, and their concentration in plasma (the fluid component of blood) is strongly predicative of cardiovascular disease and death. In a healthy human body, the majority of ADMA is eliminated through active metabolism by DDAH. Scientists have hypothesised that if DDAH function is impaired, NO production is reduced, and that this could be an important feature of increased cardiovascular risk. To examine this pathway in more detail, the researchers deleted the DDAH gene in mice. These mice went on to develop hypertension, or high blood pressure. They also designed specific inhibitors (small molecules) which bind to the active site of human DDAH. These small molecule inhibitors also induced hypertension in mice, confirming the importance of DDAH in the regulation of blood pressure. Dr Leiper, UCL Medicine, said: “These genetic and chemical approaches to disrupt DDAH showed remarkably consistent results, and provide compelling evidence that loss of DDAH function increases the concentration of ADMA and thereby disrupts vascular NO signalling. “There has been considerable scientific interest in this pathway and the role of ADMA as a novel risk factor, but so far there's been little evidence to support the idea that it's a cause of disease, rather than just a marker. Genes and their pathways are crucial to our understanding of cardiovascular disease and a better understanding of DDAH-1 could lead to important new treatments. “It could help us to establish if genetic variation predisposes certain people to these diseases, or whether environmental factors exert some of their effects through modulation of DDAH activity. “Our research also shows that this pathway could be harnessed therapeutically to limit production of NO in certain situations where too much nitric oxide is a bad thing; for example, hypotension and septic shock. These are some of the biggest problems in intensive care medicine and there is a huge unmet need for drug treatments.” The study, which was carried out at UCL's Rayne Institute, was funded by grants from the British Heart Foundation, the Wellcome Trust and the Medical Research Council. Professor Jeremy Pearson, Associate Medical Director of the British Heart Foundation, said: "The unexpected finding in the 1980s that a simple gas, nitric oxide (NO), is made by cells in the blood vessel wall and is a powerful control of blood vessel relaxation led to the award of the Nobel Prize in 1998 to its discoverers. "More recently, there has been increasing evidence that impairment of NO production is likely to be an important factor in the development of heart and circulatory disease, but the mechanisms responsible are not fully understood. "This study suggests for the first time that the loss of the activity of the enzyme DDAH-1 leads to reduced NO production and may cause heart and circulatory disease. These findings are likely to be important in the search for new ways to optimise the health of our blood vessels." ### Notes for Editors 1. For more information, please contact Ruth Metcalfe in the UCL Media Relations Office on tel: +44 (0)20 7679 9739, mobile: +44 (0)7990 675 947, out of hours: +44 (0)7917 271 364, e-mail: r.metcalfe@ucl.ac.uk2. 'Disruption of methylarginine metabolism impairs vascular homeostasis' is published in the February issue of the journal Nature Medicine. Advance online publication is embargoed to 18.00 GMT (13.00 US Eastern) Sunday 4 February 2007. Journalists can obtain copies of the paper by contacting the UCL Media Relations Office.3. The study was funded by the British Heart Foundation, the Wellcome Trust and the Medical Research Council. About UCL Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence. UCL is the fourth-ranked UK university in the 2006 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Mahatma Gandhi (Laws 1889, Indian political and spiritual leader); Jonathan Dimbleby (Philosophy 1969, writer and television presenter); Junichiro Koizumi (Economics 1969, Prime Minister of Japan); Lord Woolf (Laws 1954, Lord Chief Justice of England & Wales); Alexander Graham Bell (Phonetics 1860s, inventor of the telephone), and members of the band Coldplay.
   Similar news · Read more »
   
3. Gene found for rare disorder may reveal new pathway in mental retardation
   02-05-2007 · EurekAlert!
   Studying mutations that give rise to a rare genetic disease, genetics researchers have identified a novel biological pathway that may have a broader role during human development, potentially in cases of mental retardation and autism. An international team of researchers identified two genes that contribute to Cornelia deLange syndrome, a multisystem genetic disease that affects an estimated one in 10,000 children.
   Similar news · Read more »
   
4. Research team identifies additional genetic risk factors for Crohn's disease
   04-15-2007 · EurekAlert!
   An international research team has identified several novel genetic variations associated with the risk of Crohn's disease. One of the identified genes establishes a role for autophagy, a previously unsuspected biological pathway, in Crohn's disease pathology, and the report documents functional studies which establish that this gene is integral to immune responses to intestinal bacteria.
   Similar news · Read more »
   
5. Bits of 'junk' RNA aid master tumor-suppressor gene
   08-23-2007 · EurekAlert!
   A University of Michigan study reveals that the p53 gene, a key protector mutated in half of all cancers, gets help in its vital job of stifling tumors from a trio of little-known micro RNA genes. Drugs that mimic their benefits could become important tools in cancer therapy someday.
   Similar news · Read more »
   
6. Einstein researchers use novel approach to uncover genetic components of aging
   08-24-2007 · EurekAlert!
   People who live to 100 or more are known to have just as many -- and sometimes even more -- harmful gene variants compared with younger people. Now, scientists at the Albert Einstein College of Medicine of Yeshiva University have discovered the secret behind this paradox: favorable "longevity" genes that protect very old people from the bad genes' harmful effects. The novel method used by the researchers could lead to new drugs to protect against age-related diseases.
   Similar news · Read more »
   
7. Jefferson scientists show gene reverts cancer genes to normal, predicts breast cancer prognosis
   10-31-2006 · EurekAlert!
   Scientists have shown that the activity of a gene that commandeers other cancer-causing genes, returning them to normal, can predict the prognosis of an individual with breast cancer. They looked at cancer cells from more than 2,000 breast cancer patients and found that this commandeering or "organizing" ability is increasingly lost in cancer cells and associated with the progression of disease. The more the gene is expressed in breast cancer, the better the patient did.
   Similar news · Read more »
   
8. Unique role for blood formation gene identified
   09-12-2007 · EurekAlert!
   All blood cell production in adults depends on the steady work of a vital gene that if lost results in early bone marrow failure, Dartmouth Medical School cancer geneticists have found. Their research reveals an unexpected role for the gene in sustaining the adult blood-forming system, and opens novel strategies for targeting the gene, which is often involved in a type of childhood leukemia.
   Similar news · Read more »
   
9. New gene test for prostate cancer at hand
   01-17-2008 · EurekAlert!
   Men with susceptibility for prostate cancer will soon be identifiable through a simple DNA test. So hope scientists at the Swedish medical university Karolinska Institutet, who have shown that men carrying a combination of known risk genes run a four to five times higher risk of developing prostate cancer. At present, men with suspected prostate cancer are identified mainly using what are known as PSA tests. However, the test has a relatively low sensitivity and better methods are needed.
   Similar news · Read more »
   
10. Technology captures tumors'genetic profile, guides cancer treatment
    02-11-2007 · EurekAlert!
    A study led by Boston researchers provides the first demonstration of a practical method of screening tumors for cancer-related gene abnormalities that might be treated with "targeted" drugs. The findings may help relieve a bottleneck between scientists' expanding knowledge of the genetic mutations associated with cancer and the still nascent ability of doctors to use that knowledge to benefit patients.
    Similar news · Read more »